AASK-CO

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 AASK队列研究是一项前瞻性、观察性研究，是AASK临床试验的延伸。霍华德大学将在AASK队列研究中招收29名学生。此外，达到ESRD的AASK参与者将被邀请参加一次DNA采集。每年收集两次曝光量，包括环境、遗传、生理和社会经济因素。主要结果将由血清肌酐增加一倍、进展为终末期肾病或死亡来确定。将为没有ESRD的参与者提供适当的降压治疗。通过这种方式，该队列将直接控制肾脏疾病进展的两个主要的“已知”决定因素(高血压的治疗和肾脏保护性抗高血压药物的使用)，因此，将在推荐的高血压护理的背景下解决其研究目标。每名参与者每年将进行4-6次BP控制接触。队列研究的随访期为5年。AASK的队列研究将提供数据，增强我们对决定肾脏疾病进展的过程的理解。此外，这项研究的数据可能最终导致新的预防策略，延迟或防止ESRD的发生。 主要目标是前瞻性地确定接受推荐抗高血压治疗的患有高血压相关肾脏疾病的非裔美国人的长期肾功能病程和肾脏疾病进展的危险因素。第二个目标是确定心血管疾病的发生，并在高血压相关肾脏疾病的背景下评估其危险因素。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The AASK Cohort Study is a prospective, observational study that is an extension of the AASK Clinical trial. Howard University will enroll 29 in the AASK Cohort Study. Additionally, those AASK participants who reached ESRD will be invited to attend one visit for collection of DNA. Exposures to be collected twice/year including environmental, genetic, physiologic and socioeconomic factors. The primary outcome will be defined by the doubling of serum creatinine, progression to ESRD or death. Appropriate antihypertensive treatment will be provided to participants who do not have ESRD. In this fashion, the Cohort will directly control two of the major "known" determinants of kidney disease progression (treatment of hypertension and use of reno-protective, antihypertensive medications) and will, therefore, address its research objectives in the setting of recommended hypertensive care. 4-6 contacts for BP control will take place per year for each participant. The duration of followup in the Cohort Study will be 5 years. The AASK Cohort Study will provide data that enhances our understanding of the processes that determine progression of renal disease. Furthermore, data from this study might ultimately lead to new prevention strategies that delay or prevent the onset of ESRD. The primary objective is to prospectively determine the long-term course of kidney function and risk factors for kidney disease progression in African Americans with hypertension-related kidney disease who receive recommended antihypertension therapy. A secondary objective is to determine the occurrence of cardiovascular disease and assess its risk factors in the setting of hypertension-related kidney disease.